MATTHEW BUCHER: Open Payments
NPI 1295939791 · FRANKFORT, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$852 in 48 payments from 10 companies in 2025. Trend: 2023 $580 · 2024 $1,256 · 2025 $852
Food & beverage: $852
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $341 |
| Novo Nordisk Inc | 6 | $149 |
| AstraZeneca Pharmaceuticals LP | 8 | $139 |
| Amgen Inc. | 5 | $76 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Lilly USA, LLC | 2 | $32 |
| Alkermes, Inc. | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $14 |
Products named: QULIPTA, AIRSUPRA, VRAYLAR, OTEZLA, Ozempic, Rybelsus, TRELEGY ELLIPTA, MOUNJARO.
Industry payments across KY — which companies pay providers there.
